Terms ending in 2028
Every in-force patent on Amgen Inc.'s record whose computed term ends in 2028, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,198,448 | Fused Heterocyclic Derivatives and Methods of Use In force · Medium confidence | Amgen Inc. | In force | Medium confidence | |
| US 9,981,988 | Polymorphic Forms and Co-Crystals of a C-Met Inhibitor In force · Medium confidence | Amgen Inc. | In force | Medium confidence | |
| US 10,328,062 | Biomarkers and Use of Met Inhibitor for Treatment of Cancer In force · Medium confidence | Amgen Inc. | In force | Medium confidence | |
| US 7,759,344 | Bis-Aryl Amide Derivatives and Methods of Use In force · Medium confidence | Amgen Inc. | In force | Medium confidence | |
| US 9,283,260 | Lyophilized therapeutic peptibody Formulations In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 7,427,638 | (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione:, and Methods of Synthesis and Compositions Thereof In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 7,816,367 | Compounds, Pharmaceutical Compositions and Methods for Use in Treating Metabolic Disorders In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 7,834,162 | Methods and Systems for Isolating Target Molecules from Complex Solutions by Column-Chromatography Using Eluants Containing Organic Solvents In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 7,585,500 | Fully Human Monoclonal Antibodies to IL-13 In force · High confidence | Amgen Fremont Inc. | In force | High confidence | |
| US 8,021,333 | Syringe Spring Retainer In force · High confidence | Amgen Inc. | In force | High confidence | |
| 64 more term ends in 2028 · Pro | |||||
10 of 74 patents shown. Soonest term end first, then patent number.
Pro members see all 74, including 23 expiring within the 18 months from Nov 20, 2026.
72 of these are in force and held by Amgen Inc..
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.